NCT03507998View on ClinicalTrials.gov

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 17, 2017

Primary Completion Date

April 1, 2021

Study Completion Date

April 1, 2021

Conditions
Colorectal AdenocarcinomaGastric AdenocarcinomaPancreatic AdenocarcinomaBile Duct CarcinomaHepatocellular CarcinomaEsophageal CarcinomaGastrointestinal Cancer
Interventions
DRUG

CGX1321

CGX1321 capsules for oral administration

Trial Locations (2)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors

Lead Sponsor

Curegenix Inc.
All Listed Sponsors
collaborator

Guangzhou Curegenix Co. Ltd.

UNKNOWN

lead

Curegenix Inc.

INDUSTRY